FDA Approves Topical Ruxolitinib for Nonsegmental Vitiligo

The topical formulation of the JAK1/JAK2 inhibitor was previously approved for atopic dermatitis.
FDA Approvals

source https://www.medscape.com/viewarticle/977464?src=rss